[1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67:7-30. doi:10.3322/caac.21387.
|
[2] |
Andersen DK. Diabetes and cancer: placing the association in perspective[J]. Curr Opin Endocrinol Diabetes Obes, 2013, 20: 81-86. doi:10.1097/MED.0b013e32835eddd3.
|
[3] |
Li D, Tang H, Hassan MM, et al. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies[J]. Cancer Causes Control, 2011, 22: 189-197. doi:10.1007/s10552-010-9686-3.
|
[4] |
Liao WC, Tu YK, Wu MS, et al. Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis[J]. British Medical Journal,2015, 350: g7371. doi:10.1136/bmj.g7371.
|
[5] |
Karnevi E, Said K, Andersson R, et al. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells[J]. BMC Cancer, 2013, 13: 235-245. doi:10.1186/1471-2407-13-235
|
[6] |
Duan W, Chen K, Jiang Z, et al. Desmoplasia suppres-sion by metformin-mediated AMPK activation inhibits pancreatic cancer progression[J]. Cancer Lett, 2017,385:225-233.DOI:10.1016/j.canlet.2016.10.019.
|
[7] |
Hua S, Lei L, Deng L, et al. miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1[J]. Oncogene, 2018, 37: 1624-1636. doi:10.1038/s41388-017-0057-3.
|
[8] |
Zordoky BN, Bark D, Soltys CL, et al. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention[J]. Biochim Biophys Acta, 2014, 1840: 1943-1957. doi:10.1016/j.bbagen.2014.01.023.
|
[9] |
Sinnett-Smith J, Kisfalvi K, Kui R, et al. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK[J]. Biochem Biophys Res Commun, 2013, 430: 352-357. doi:10.1016/j.bbrc.2012.11.010.
|
[10] |
Bikas A, Jensen K, Patel A, et al. Glucose-deprivation increases thyroid cancer cells sensitivity to metformin[J]. Endocr Relat Cancer, 2015, 22: 919-932. doi:10.1530/ERC-15-0402.
|
[11] |
Zhuang Y, Chan DK, Haugrud AB, et al. Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo[J]. PLoS One, 2014, 9: e108444. doi:10.1371/journal.pone.0108444.
|
[12] |
Queiroz EA, Puukila S, Eichler R, et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells[J]. PLoS One, 2014, 9: e98207. doi:10.1371/journal.pone.0098207.
|
[13] |
Xie W, Wang L, Sheng H, et al. Metformin induces growth inhibition and cell cycle arrest by upregulating microRNA34a in renal cancer cells[J]. Med Sci Monit,2017, 23: 29-37. doi:10.12659/msm.898710.
|
[14] |
Hamed SS, Straubinger RM, Jusko WJ. Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells[J]. Cancer Chemo-ther Pharmacol, 2013, 72: 553-563. doi:10.1007/s00280-013-2226-6.
|
[15] |
Qian W, Li J, Chen K, et al. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancrea-tic cancer[J]. Life Sci, 2018, 208: 253-261. doi:10.1016/j.lfs.2018.07.046.
|